Compare Stocks

3 / 10
Try these comparisons:

Stock Comparison

SYRA vs TALK vs ACMR

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
SYRA
Syra Health Corp. Class A Common Stock

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$6M
5Y Perf.-83.3%
TALK
Talkspace, Inc.

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$868M
5Y Perf.+165.6%
ACMR
ACM Research, Inc.

Semiconductors

TechnologyNASDAQ • US
Market Cap$3.92B
5Y Perf.+227.0%

SYRA vs TALK vs ACMR — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
SYRA logoSYRA
TALK logoTALK
ACMR logoACMR
IndustryMedical - Care FacilitiesMedical - Care FacilitiesSemiconductors
Market Cap$6M$868M$3.92B
Revenue (TTM)$8M$229M$901M
Net Income (TTM)$-183K$8M$94M
Gross Margin33.2%43.0%44.4%
Operating Margin-3.1%1.4%12.1%
Forward P/E38.2x29.7x
Total Debt$144K$0.00$303M
Cash & Equiv.$2M$37M$766M

SYRA vs TALK vs ACMRLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

SYRA
TALK
ACMR
StockSep 23May 26Return
Syra Health Corp. C… (SYRA)10016.7-83.3%
Talkspace, Inc. (TALK)100265.6+165.6%
ACM Research, Inc. (ACMR)100327.0+227.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: SYRA vs TALK vs ACMR

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ACMR leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Syra Health Corp. Class A Common Stock is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
SYRA
Syra Health Corp. Class A Common Stock
The Income Pick

SYRA is the clearest fit if your priority is income & stability and sleep-well-at-night.

  • beta 0.19
  • Lower volatility, beta 0.19, Low D/E 6.9%, current ratio 4.06x
  • Beta 0.19, current ratio 4.06x
Best for: income & stability and sleep-well-at-night
TALK
Talkspace, Inc.
The Growth Play

TALK is the clearest fit if your priority is growth exposure.

  • Rev growth 22.0%, EPS growth 6.5%, 3Y rev CAGR 24.2%
  • 22.0% revenue growth vs SYRA's -9.5%
  • 5.9% ROA vs SYRA's -5.4%, ROIC 3.9% vs -86.8%
Best for: growth exposure
ACMR
ACM Research, Inc.
The Long-Run Compounder

ACMR has the current edge in this matchup, primarily because of its strength in long-term compounding.

  • 30.7% 10Y total return vs TALK's -48.7%
  • Lower P/E (29.7x vs 38.2x)
  • 10.4% margin vs SYRA's -2.4%
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthTALK logoTALK22.0% revenue growth vs SYRA's -9.5%
ValueACMR logoACMRLower P/E (29.7x vs 38.2x)
Quality / MarginsACMR logoACMR10.4% margin vs SYRA's -2.4%
Stability / SafetySYRA logoSYRABeta 0.19 vs ACMR's 3.24, lower leverage
DividendsACMR logoACMR0.2% yield; 3-year raise streak; the other 2 pay no meaningful dividend
Momentum (1Y)SYRA logoSYRA+5.2% vs TALK's +70.4%
Efficiency (ROA)TALK logoTALK5.9% ROA vs SYRA's -5.4%, ROIC 3.9% vs -86.8%

SYRA vs TALK vs ACMR — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

SYRASyra Health Corp. Class A Common Stock
FY 2025
Population Health
100.0%$5M
TALKTalkspace, Inc.

Segment breakdown not available.

ACMRACM Research, Inc.
FY 2025
Total Single Wafer and Semi-Critical Cleaning Equipment
69.5%$626M
ECP Front End And Packaging Furnace And Other Technologies
22.1%$200M
Advanced Packaging (exclude ECP), Services & Spares
8.4%$76M

SYRA vs TALK vs ACMR — Financial Metrics

Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLACMRLAGGINGTALK

Income & Cash Flow (Last 12 Months)

ACMR leads this category, winning 3 of 6 comparable metrics.

ACMR is the larger business by revenue, generating $901M annually — 117.9x SYRA's $8M. ACMR is the more profitable business, keeping 10.4% of every revenue dollar as net income compared to SYRA's -2.4%. On growth, TALK holds the edge at +29.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricSYRA logoSYRASyra Health Corp.…TALK logoTALKTalkspace, Inc.ACMR logoACMRACM Research, Inc.
RevenueTrailing 12 months$8M$229M$901M
EBITDAEarnings before interest/tax-$227,636$7M$126M
Net IncomeAfter-tax profit-$183,089$8M$94M
Free Cash FlowCash after capex$755,858-$2M-$69M
Gross MarginGross profit ÷ Revenue+33.2%+43.0%+44.4%
Operating MarginEBIT ÷ Revenue-3.1%+1.4%+12.1%
Net MarginNet income ÷ Revenue-2.4%+3.4%+10.4%
FCF MarginFCF ÷ Revenue+9.9%-0.9%-7.6%
Rev. Growth (YoY)Latest quarter vs prior year+22.4%+29.3%+9.4%
EPS Growth (YoY)Latest quarter vs prior year+130.8%-76.1%
ACMR leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

ACMR leads this category, winning 3 of 5 comparable metrics.

At 43.2x trailing earnings, ACMR trades at a 67% valuation discount to TALK's 129.5x P/E. On an enterprise value basis, ACMR's 27.5x EV/EBITDA is more attractive than TALK's 137.8x.

MetricSYRA logoSYRASyra Health Corp.…TALK logoTALKTalkspace, Inc.ACMR logoACMRACM Research, Inc.
Market CapShares × price$6M$868M$3.9B
Enterprise ValueMkt cap + debt − cash$4M$830M$3.5B
Trailing P/EPrice ÷ TTM EPS-6.62x129.50x43.21x
Forward P/EPrice ÷ next-FY EPS est.38.20x29.68x
PEG RatioP/E ÷ EPS growth rate1.22x
EV / EBITDAEnterprise value multiple137.77x27.49x
Price / SalesMarket cap ÷ Revenue0.79x3.79x4.35x
Price / BookPrice ÷ Book value/share2.83x7.69x2.06x
Price / FCFMarket cap ÷ FCF
ACMR leads this category, winning 3 of 5 comparable metrics.

Profitability & Efficiency

Evenly matched — TALK and ACMR each lead in 4 of 9 comparable metrics.

TALK delivers a 6.9% return on equity — every $100 of shareholder capital generates $7 in annual profit, vs $-8 for SYRA. SYRA carries lower financial leverage with a 0.07x debt-to-equity ratio, signaling a more conservative balance sheet compared to ACMR's 0.16x. On the Piotroski fundamental quality scale (0–9), TALK scores 6/9 vs ACMR's 2/9, reflecting solid financial health.

MetricSYRA logoSYRASyra Health Corp.…TALK logoTALKTalkspace, Inc.ACMR logoACMRACM Research, Inc.
ROE (TTM)Return on equity-8.1%+6.9%+6.1%
ROA (TTM)Return on assets-5.4%+5.9%+3.9%
ROICReturn on invested capital-86.8%+3.9%+7.0%
ROCEReturn on capital employed-35.0%+2.7%+6.6%
Piotroski ScoreFundamental quality 0–9562
Debt / EquityFinancial leverage0.07x0.16x
Net DebtTotal debt minus cash-$1M-$37M-$463M
Cash & Equiv.Liquid assets$2M$37M$766M
Total DebtShort + long-term debt$143,787$0$303M
Interest CoverageEBIT ÷ Interest expense-55.59x20.44x
Evenly matched — TALK and ACMR each lead in 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — SYRA and TALK and ACMR each lead in 2 of 6 comparable metrics.

A $10,000 investment in ACMR five years ago would be worth $23,344 today (with dividends reinvested), compared to $1,668 for SYRA. Over the past 12 months, SYRA leads with a +517.7% total return vs TALK's +70.4%. The 3-year compound annual growth rate (CAGR) favors TALK at 80.7% vs SYRA's -45.0% — a key indicator of consistent wealth creation.

MetricSYRA logoSYRASyra Health Corp.…TALK logoTALKTalkspace, Inc.ACMR logoACMRACM Research, Inc.
YTD ReturnYear-to-date+475.1%+47.6%+31.9%
1-Year ReturnPast 12 months+517.7%+70.4%+195.6%
3-Year ReturnCumulative with dividends-83.3%+490.0%+487.9%
5-Year ReturnCumulative with dividends-83.3%-47.7%+133.4%
10-Year ReturnCumulative with dividends-83.3%-48.7%+3065.8%
CAGR (3Y)Annualised 3-year return-45.0%+80.7%+80.5%
Evenly matched — SYRA and TALK and ACMR each lead in 2 of 6 comparable metrics.

Risk & Volatility

Evenly matched — SYRA and TALK each lead in 1 of 2 comparable metrics.

SYRA is the less volatile stock with a 0.19 beta — it tends to amplify market swings less than ACMR's 3.24 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TALK currently trades 99.6% from its 52-week high vs SYRA's 71.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSYRA logoSYRASyra Health Corp.…TALK logoTALKTalkspace, Inc.ACMR logoACMRACM Research, Inc.
Beta (5Y)Sensitivity to S&P 5000.19x0.86x3.24x
52-Week HighHighest price in past year$0.70$5.20$71.65
52-Week LowLowest price in past year$0.05$2.22$19.26
% of 52W HighCurrent price vs 52-week peak+71.5%+99.6%+82.6%
RSI (14)Momentum oscillator 0–10055.662.760.7
Avg Volume (50D)Average daily shares traded47K4.5M1.2M
Evenly matched — SYRA and TALK each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: TALK as "Hold", ACMR as "Buy". Consensus price targets imply 1.4% upside for TALK (target: $5) vs -32.4% for ACMR (target: $40). ACMR is the only dividend payer here at 0.19% yield — a key consideration for income-focused portfolios.

MetricSYRA logoSYRASyra Health Corp.…TALK logoTALKTalkspace, Inc.ACMR logoACMRACM Research, Inc.
Analyst RatingConsensus buy/hold/sellHoldBuy
Price TargetConsensus 12-month target$5.25$40.00
# AnalystsCovering analysts1010
Dividend YieldAnnual dividend ÷ price+0.2%
Dividend StreakConsecutive years of raises3
Dividend / ShareAnnual DPS$0.11
Buyback YieldShare repurchases ÷ mkt cap0.0%+2.0%+0.2%
Insufficient data to determine a leader in this category.
Key Takeaway

ACMR leads in 2 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 3 categories are tied.

Best OverallACM Research, Inc. (ACMR)Leads 2 of 6 categories
Loading custom metrics...

SYRA vs TALK vs ACMR: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is SYRA or TALK or ACMR a better buy right now?

For growth investors, Talkspace, Inc.

(TALK) is the stronger pick with 22. 0% revenue growth year-over-year, versus -9. 5% for Syra Health Corp. Class A Common Stock (SYRA). ACM Research, Inc. (ACMR) offers the better valuation at 43. 2x trailing P/E (29. 7x forward), making it the more compelling value choice. Analysts rate ACM Research, Inc. (ACMR) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — SYRA or TALK or ACMR?

On trailing P/E, ACM Research, Inc.

(ACMR) is the cheapest at 43. 2x versus Talkspace, Inc. at 129. 5x. On forward P/E, ACM Research, Inc. is actually cheaper at 29. 7x.

03

Which is the better long-term investment — SYRA or TALK or ACMR?

Over the past 5 years, ACM Research, Inc.

(ACMR) delivered a total return of +133. 4%, compared to -83. 3% for Syra Health Corp. Class A Common Stock (SYRA). Over 10 years, the gap is even starker: ACMR returned +30. 7% versus SYRA's -83. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — SYRA or TALK or ACMR?

By beta (market sensitivity over 5 years), Syra Health Corp.

Class A Common Stock (SYRA) is the lower-risk stock at 0. 19β versus ACM Research, Inc. 's 3. 24β — meaning ACMR is approximately 1633% more volatile than SYRA relative to the S&P 500. On balance sheet safety, Syra Health Corp. Class A Common Stock (SYRA) carries a lower debt/equity ratio of 7% versus 16% for ACM Research, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — SYRA or TALK or ACMR?

By revenue growth (latest reported year), Talkspace, Inc.

(TALK) is pulling ahead at 22. 0% versus -9. 5% for Syra Health Corp. Class A Common Stock (SYRA). On earnings-per-share growth, the picture is similar: Syra Health Corp. Class A Common Stock grew EPS 85. 5% year-over-year, compared to -10. 5% for ACM Research, Inc.. Over a 3-year CAGR, ACMR leads at 32. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — SYRA or TALK or ACMR?

ACM Research, Inc.

(ACMR) is the more profitable company, earning 10. 4% net margin versus -12. 4% for Syra Health Corp. Class A Common Stock — meaning it keeps 10. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACMR leads at 12. 1% versus -12. 5% for SYRA. At the gross margin level — before operating expenses — ACMR leads at 44. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is SYRA or TALK or ACMR more undervalued right now?

On forward earnings alone, ACM Research, Inc.

(ACMR) trades at 29. 7x forward P/E versus 38. 2x for Talkspace, Inc. — 8. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TALK: 1. 4% to $5. 25.

08

Which pays a better dividend — SYRA or TALK or ACMR?

In this comparison, ACMR (0.

2% yield) pays a dividend. SYRA, TALK do not pay a meaningful dividend and should not be held primarily for income.

09

Is SYRA or TALK or ACMR better for a retirement portfolio?

For long-horizon retirement investors, Syra Health Corp.

Class A Common Stock (SYRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 19)). ACM Research, Inc. (ACMR) carries a higher beta of 3. 24 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYRA: -83. 3%, ACMR: +30. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between SYRA and TALK and ACMR?

These companies operate in different sectors (SYRA (Healthcare) and TALK (Healthcare) and ACMR (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SYRA is a small-cap quality compounder stock; TALK is a small-cap high-growth stock; ACMR is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

SYRA

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 11%
  • Gross Margin > 19%
Run This Screen
Stocks Like

TALK

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Gross Margin > 25%
Run This Screen
Stocks Like

ACMR

Steady Growth Compounder

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 6%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform SYRA and TALK and ACMR on the metrics below

Revenue Growth>
%
(SYRA: 22.4% · TALK: 29.3%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.